{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:53:56Z","timestamp":1791561236643,"version":"4.3.4"},"reference-count":218,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T00:00:00Z","timestamp":1639353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The impact of new and emerging therapies on the microenvironment of primary cutaneous lymphomas (PCLs) has been recently raised in the literature. Concomitantly, novel treatments are already used or registered (dupilumab, upadacitinib) and others seem to be added to the armamentarium against atopic dermatitis. Our aim was to review the literature on interleukins 4, 13, 22, and 31, and JAK\/STAT pathways in PCLs to elucidate the safety of using biologics (dupilumab, tralokinumab, fezakinumab, nemolizumab) and small molecule inhibitors (upadacitinib, baricitinib, abrocitinib, ruxolitinib, tofacitinib) in the treatment of atopic dermatitis. We summarized the current state of knowledge on this topic based on the search of the PubMed database and related references published before 21 October 2021. Our analysis suggests that some of the mentioned agents (dupilumab, ruxolitinib) and others may have a direct impact on the progression of cutaneous lymphomas. This issue requires further study and meticulous monitoring of patients receiving these drugs to ensure their safety, especially in light of the FDA warning on tofacitinib. In conclusion, in the case of the rapid progression of atopic dermatitis\/eczema, especially in patients older than 40 years old, there is a necessity to perform a biopsy followed by a very careful pathological examination.<\/jats:p>","DOI":"10.3390\/ijms222413388","type":"journal-article","created":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T01:20:41Z","timestamp":1639444841000},"page":"13388","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Safety and Danger Considerations of Novel Treatments for Atopic Dermatitis in Context of Primary Cutaneous Lymphomas"],"prefix":"10.3390","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5977-2126","authenticated-orcid":false,"given":"Karol","family":"Ko\u0142kowski","sequence":"first","affiliation":[{"name":"Dermatological Students Scientific Association, Department of Dermatology, Venereology and Allergology, Faculty of Medicine, Medical University of Gdansk, 80-214 Gdansk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8206-8441","authenticated-orcid":false,"given":"Magdalena","family":"Trzeciak","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology, Faculty of Medicine, Medical University of Gdansk, 80-214 Gdansk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7626-3689","authenticated-orcid":false,"given":"Ma\u0142gorzata","family":"Soko\u0142owska-Wojdy\u0142o","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology, Faculty of Medicine, Medical University of Gdansk, 80-214 Gdansk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/CCO.0000000000000243","article-title":"Tumor microenvironment in mycosis fungoides and S\u00e9zary syndrome","volume":"28","author":"Gonzalez","year":"2016","journal-title":"Curr. Opin. Oncol."},{"key":"ref_3","first-page":"401","article-title":"Novel Targeted Biological Agents for the Treatment of Atopic Dermatitis","volume":"35","author":"Yang","year":"2021","journal-title":"BioDrugs 2021"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"293","DOI":"10.5414\/ALX02272E","article-title":"Janus kinase inhibitors for the therapy of atopic dermatitis","volume":"5","author":"Traidl","year":"2021","journal-title":"Allergol. Sel."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Szalus, K., Trzeciak, M., and Nowicki, R.J. (2020). Jak-stat inhibitors in atopic dermatitis from pathogenesis to clinical trials results. Microorganisms, 8.","DOI":"10.3390\/microorganisms8111743"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1345\/aph.1M278","article-title":"Association between exposure to topical tacrolimus or pimecrolimus and cancers","volume":"43","author":"Hui","year":"2009","journal-title":"Ann. Pharmacother."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/bjd.18451","article-title":"Higher self-reported severity of atopic dermatitis in adults is associated with poorer self-reported health-related quality of life in France, Germany, the U.K. and the U.S.A","volume":"182","author":"Andersen","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(06)69283-0","article-title":"Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys","volume":"368","author":"Asher","year":"2006","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Hou, A., and Silverberg, J.I. (2021). Secular trends of atopic dermatitis and its comorbidities in United States children between 1997 and 2018. Arch. Dermatol. Res., in press.","DOI":"10.1007\/s00403-021-02219-w"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s13555-021-00516-w","article-title":"Epidemiology and Characterization of Atopic Dermatitis in East Asian Populations: A Systematic Review","volume":"11","author":"Cheng","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/ijd.14891","article-title":"Atopic dermatitis in the elderly Caucasian population: Diagnostic clinical criteria and review of the literature","volume":"59","author":"Chello","year":"2020","journal-title":"Int. J. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/all.13401","article-title":"Epidemiology of atopic dermatitis in adults: Results from an international survey","volume":"73","author":"Barbarot","year":"2018","journal-title":"Allergy Eur. J. Allergy Clin. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.jaci.2017.07.006","article-title":"Therapeutic pipeline for atopic dermatitis: End of the drought?","volume":"140","author":"Paller","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.jaad.2015.02.1116","article-title":"Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: A systematic review and meta-analysis","volume":"72","author":"Legendre","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1001\/jamadermatol.2020.1948","article-title":"Association between Atopic Eczema and Cancer in England and Denmark","volume":"156","author":"Mansfield","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.jaci.2009.02.028","article-title":"Lymphoma among patients with atopic dermatitis and\/or treated with topical immunosuppressants in the United Kingdom","volume":"123","author":"Arellano","year":"2009","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jdermsci.2011.07.007","article-title":"Erythrodermic cutaneous T-cell lymphoma: How to differentiate this rare disease from atopic dermatitis","volume":"64","author":"Miyagaki","year":"2011","journal-title":"J. Dermatol. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"7529","DOI":"10.1158\/1078-0432.CCR-11-1192","article-title":"IL-22, but not IL-17, Dominant environment in cutaneous T-cell lymphoma","volume":"17","author":"Miyagaki","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1182\/blood.V89.1.32.32_32_40","article-title":"Association of erythrodermic cutaneous T-cell lymphoma, superantigen- positive Staphylococcus aureus, and oligoclonal T-cell receptor V\u03b2 gene expansion","volume":"89","author":"Jackow","year":"1997","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/j.1365-2133.2006.07410.x","article-title":"Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: A double-blind multicentre randomized controlled trial","volume":"155","author":"Gong","year":"2006","journal-title":"Br. J. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/1523-1747.ep12611877","article-title":"Aberrant cytokine production by sezary syndrome patients: Cytokine secretion pattern resembles murine TH2 cells","volume":"99","author":"Vowels","year":"1992","journal-title":"J. Investig. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/1523-1747.ep12398454","article-title":"Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma","volume":"103","author":"Vowels","year":"1994","journal-title":"J. Investig. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/1523-1747.ep12388985","article-title":"Mycosis fungoides exhibits a Th1-type cell-mediated cytokine profile whereas sezary syndrome expresses a Th2-type profile","volume":"103","author":"Saed","year":"1994","journal-title":"J. Investig. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.coi.2017.08.008","article-title":"Atopic dermatitis and psoriasis: Two different immune diseases or one spectrum?","volume":"48","author":"Krueger","year":"2017","journal-title":"Curr. Opin. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMra074081","article-title":"Atopic dermatitis","volume":"358","author":"Bieber","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Trzeciak, M., Olszewska, B., Sakowicz-Burkiewicz, M., Soko\u0142owska-Wojdy\u0142o, M., Jankau, J., Nowicki, R.J., and Pawe\u0142czyk, T. (2020). Expression Profiles of Genes Encoding Cornified Envelope Proteins in Atopic Dermatitis and Cutaneous T-Cell Lymphomas. Nutrients, 12.","DOI":"10.3390\/nu12030862"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1158\/1078-0432.CCR-14-0077","article-title":"Skin Barrier Dysfunction and Low Antimicrobial Peptide Expression in Cutaneous T-cell Lymphoma","volume":"20","author":"Suga","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/ACI.0b013e328364ddfd","article-title":"Expression of antimicrobial peptides in atopic dermatitis and possible immunoregulatory functions","volume":"13","author":"Kopfnagel","year":"2013","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Saulite, I., Hoetzenecker, W., Weidinger, S., Cozzio, A., Guenova, E., and Wehkamp, U. (2016). S\u00e9zary Syndrome and Atopic Dermatitis: Comparison of Immunological Aspects and Targets. BioMed Res. Int., 2016.","DOI":"10.1155\/2016\/9717530"},{"key":"ref_30","unstructured":"(2021, October 16). A Study Investigating the Efficacy, Safety, and PK Profile of ANB020 Administered to Adult Subjects with Moderate-to-Severe AD (ATLAS), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03533751?term=ANB020&cond=Atopic+Dermatitis&rank=1."},{"key":"ref_31","unstructured":"(2021, October 16). A Study to Evaluate the Safety and Efficacy of PF-06826647 in Participants with Moderate to Severe Ulcerative Colitis\u2014Full Text View\u2014ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04209556?term=PF-06826647&cond=ulcerative+colitis&draw=2&rank=1."},{"key":"ref_32","unstructured":"(2021, October 16). NCT03568071\u2014A Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics (PK)\/Pharmacodynamics (PD) of MOR106 in Subjects with Moderate to Severe Atopic Dermatitis. Available online: https:\/\/www.cochranelibrary.com\/central\/doi\/10.1002\/central\/CN-01660617\/full."},{"key":"ref_33","unstructured":"(2021, October 16). A Study to Test Safety, Tolerability, and the Way the Body Absorbs, Distributes, and Gets Rid of a Study Drug Called MOR106, in Healthy Subjects and in Patients with Moderate to Severe Atopic Dermatitis\u2014Full Text View\u2014ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03689829?term=MOR106&cond=Atopic+Dermatitis&draw=2&rank=3."},{"key":"ref_34","unstructured":"(2021, October 16). Study of Single and Multiple Doses of ALS-008176 in Healthy Volunteers\u2014Full Text View\u2014ClinicalTrials.gov, Available online: http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01906164?term=ALS-008176&rank=1."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/all.14050","article-title":"Efficacy and safety of mepolizumab administered subcutaneously for moderate to severe atopic dermatitis","volume":"75","author":"Kang","year":"2020","journal-title":"Allergy Eur. J. Allergy Clin. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Husein-ElAhmed, H., and Steinhoff, M. (2021). Effectiveness of ustekinumab in patients with atopic dermatitis: Analysis of real-world evidence. J. Dermatol. Treat., in press.","DOI":"10.1080\/09546634.2021.1914315"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jaad.2020.12.026","article-title":"The Immunopathogenesis and Immunotherapy of Cutaneous T Cell Lymphoma: Part II, Current and Future Approaches","volume":"84","author":"Weiner","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd4624","article-title":"Targeting key proximal drivers of type 2 inflammation in disease","volume":"15","author":"Gandhi","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/1744666X.2017.1298443","article-title":"Commonality of the IL-4\/IL-13 pathway in atopic diseases","volume":"13","author":"Gandhi","year":"2017","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1007\/s13555-021-00558-0","article-title":"Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials","volume":"11","author":"Griffiths","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.jmb.2013.01.024","article-title":"Structural basis of signaling blockade by anti-IL-13 antibody Lebrikizumab","volume":"425","author":"Ultsch","year":"2013","journal-title":"J. Mol. Biol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jamadermatol.2020.0079","article-title":"Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial","volume":"156","author":"Blauvelt","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2018.01.017","article-title":"Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE)","volume":"78","author":"Simpson","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_44","unstructured":"(2021, August 17). A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults with Atopic Dermatitis (ADopt-VA)\u2014Full Text View\u2014ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04626297?term=lebrikizumab&cond=Atopic+Dermatitis&phase=2&draw=2&rank=1."},{"key":"ref_45","unstructured":"(2021, August 17). Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants with Moderate-to-Severe Atopic Dermatitis\u2014Full Text View\u2014ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04250350?term=lebrikizumab&cond=Atopic+Dermatitis&phase=2&draw=2&rank=2."},{"key":"ref_46","unstructured":"(2021, August 17). Long-Term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants with Moderate-to-Severe Atopic Dermatitis (ADjoin)\u2014Full Text View\u2014ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04392154?term=lebrikizumab&cond=Atopic+Dermatitis&phase=2&draw=2&rank=3."},{"key":"ref_47","unstructured":"(2021, August 17). Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis\u2014Full Text View\u2014ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04178967?term=lebrikizumab&cond=Atopic+Dermatitis&phase=2&draw=2&rank=4."},{"key":"ref_48","unstructured":"(2021, August 17). Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1)\u2014Full Text View\u2014ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04146363?term=lebrikizumab&cond=Atopic+Dermatitis&phase=2&draw=2&rank=5."},{"key":"ref_49","unstructured":"(2021, August 17). Safety and Efficacy of Lebrikizumab (LY3650150) in Combination with Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis\u2014Full Text View\u2014ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04250337?term=lebrikizumab&cond=Atopic+Dermatitis&phase=2&draw=2&rank=6."},{"key":"ref_50","unstructured":"(2021, August 17). A Study of Lebrikizumab (LY3650150) in Combination with Topical Corticosteroids in Japanese Participants with Moderate-to-Severe Atopic Dermatitis\u2014Full Text View\u2014ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04760314?term=lebrikizumab&cond=Atopic+Dermatitis&phase=2&draw=2&rank=7."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jmb.2016.12.005","article-title":"Structural Characterisation Reveals Mechanism of IL-13-Neutralising Monoclonal Antibody Tralokinumab as Inhibition of Binding to IL-13R\u03b11 and IL-13R\u03b12","volume":"429","author":"Popovic","year":"2017","journal-title":"J. Mol. Biol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: Results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/bjd.19573","article-title":"Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: Results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial","volume":"184","author":"Silverberg","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Abreu, M., Miranda, M., Castro, M., Fernandes, I., Cabral, R., Santos, A.H., Fonseca, S., Rodrigues, J., Leander, M., and Lau, C. (2021). IL-31 and IL-8 in Cutaneous T-Cell Lymphoma: Looking for Their Role in Itch. Adv. Hematol., 2021.","DOI":"10.1155\/2021\/5582581"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jaad.2018.01.016","article-title":"Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial","volume":"78","author":"Brunner","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJMoa1917006","article-title":"Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus","volume":"383","author":"Kabashima","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1606490","article-title":"Anti\u2013Interleukin-31 Receptor A Antibody for Atopic Dermatitis","volume":"376","author":"Ruzicka","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1080\/09546634.2017.1290205","article-title":"Interleukin-31 pathway and its role in atopic dermatitis: A systematic review","volume":"28","author":"Saleem","year":"2017","journal-title":"J. Dermatol. Treat."},{"key":"ref_59","unstructured":"(2021, August 17). Long-Term Safety and Efficacy of Nemolizumab with Moderate-to-Severe Atopic Dermatitis\u2014Full Text View\u2014ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03989206?term=nemolizumab&cond=Atopic+Dermatitis&phase=2&draw=2&rank=3."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.jaci.2021.08.009","article-title":"JAK inhibitors in the treatment of atopic dermatitis","volume":"148","author":"Chovatiya","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_61","unstructured":"Chapman, S., Kwa, M., Gold, L.S., and Lim, H.W. (2021). Janus kinase inhibitors in dermatology: Part, I. A comprehensive review. J. Am. Acad. Dermatol., in press."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/bjd.18898","article-title":"Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: Results from two randomized monotherapy phase III trials","volume":"183","author":"Simpson","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jaad.2021.02.028","article-title":"Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5)","volume":"85","author":"Simpson","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","article-title":"Efficacy and Safety of Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial","volume":"156","author":"Silverberg","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1001\/jamadermatol.2020.3260","article-title":"Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: A randomized clinical trial","volume":"156","author":"Reich","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_66","unstructured":"(2021, October 20). Lilly Lilly and Incyte Announce Top-Line Results from Phase 3 Study (BREEZE-AD4) of Oral Selective JAK Inhibitor Baricitinib in Combination with Topical Corticosteroids in Patients with Moderate to Severe Atopic Dermatitis Not Controlled with Cyclosporine. Available online: https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lilly-and-incyte-announce-top-line-results-phase-3-study-breeze."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/jdv.16948","article-title":"Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials","volume":"35","author":"Bieber","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","article-title":"Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): A multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"396","author":"Simpson","year":"2020","journal-title":"Lancet"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","article-title":"Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis","volume":"384","author":"Bieber","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Silverberg, J.I., de Bruin-Weller, M., Bieber, T., Soong, W., Kabashima, K., Costanzo, A., Rosmarin, D., Lynde, C., Liu, J., and Gamelli, A. (2021). Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results. J. Allergy Clin. Immunol.","DOI":"10.1016\/j.jaci.2021.07.036"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","article-title":"Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): Results from two replicate double-blind, randomised controlled phase 3 trials","volume":"397","author":"Teixeira","year":"2021","journal-title":"Lancet"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","article-title":"Efficacy and Safety of Upadacitinib vs Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial","volume":"157","author":"Blauvelt","year":"2021","journal-title":"JAMA Dermatol."},{"key":"ref_73","unstructured":"(2021, October 21). Open-Label Extension Study of Upadacitinib in Adult Participants with Moderate to Severe Atopic Dermatitis, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04195698?term=NCT04195698&draw=2&rank=1."},{"key":"ref_74","unstructured":"(2021, October 21). A Study to Assess Real-World Use, Safety, and Effectiveness of Oral Upadacitinib in Adult and Adolescent (\u226512 Years Old) Participants with Atopic Dermatitis\u2014Full Text View\u2014ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05081557?term=upadacitinib&cond=Atopic+Dermatitis&draw=2&rank=6."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2021.04.085","article-title":"Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies","volume":"85","author":"Papp","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_76","unstructured":"(2021, October 21). A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children with Atopic Dermatitis (TRuE-AD3)\u2014Full Text View\u2014ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04921969."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jaad.2019.12.015","article-title":"Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study","volume":"82","author":"Nakagawa","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_78","unstructured":"(2021, October 23). Efficacy and Safety of Delgocitinib Cream in Adults with Moderate to Severe Chronic Hand Eczema\u2014Full Text View\u2014ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04871711?term=delgocitinib&draw=2&rank=9."},{"key":"ref_79","unstructured":"(2021, October 23). Efficacy and Safety of Delgocitinib Cream in Adults with Moderate to Severe Chronic Hand Eczema (DELTA 2)\u2014Full Text View\u2014ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04872101?term=delgocitinib&draw=2&rank=8."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/1523-1747.ep12330869","article-title":"Progression of mycosis fungoides is associated with increasing cutaneous expression of interleukin-10 mRNA","volume":"107","author":"Asadullah","year":"1996","journal-title":"J. Investig. Dermatol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1182\/blood-2014-07-590398","article-title":"Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation","volume":"125","author":"Geskin","year":"2015","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1158\/1078-0432.CCR-12-3488","article-title":"TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma","volume":"19","author":"Guenova","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1111\/jdv.12299","article-title":"Genetic markers associated with progression in early mycosis fungoides","volume":"28","author":"Johnson","year":"2014","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1468-3083.2012.04495.x","article-title":"Increased CCL18 expression in patients with cutaneous T-cell lymphoma: Association with disease severity and prognosis","volume":"27","author":"Miyagaki","year":"2013","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/PL00007454","article-title":"T-cell clones from early-stage cutaneous T-cell lymphoma show no polarized Th-1 or Th-2 cytokine profile","volume":"292","author":"Harwix","year":"2000","journal-title":"Arch. Dermatol. Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/exd.12873","article-title":"The possible interaction between periostin expressed by cancer stroma and tumor-associated macrophages in developing mycosis fungoides","volume":"25","author":"Furudate","year":"2016","journal-title":"Exp. Dermatol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.0906-6705.2005.00294.x","article-title":"In vitro culture of skin-homing T lymphocytes from inflammatory skin diseases","volume":"14","author":"Bang","year":"2005","journal-title":"Exp. Dermatol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1182\/blood-2005-03-1139","article-title":"Skin-derived interleukin-7 contributes to the proliferation of lymphocytes in cutaneous T-cell lymphoma","volume":"107","author":"Yamanaka","year":"2006","journal-title":"Blood"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jdermsci.2016.05.004","article-title":"Tumor-associated M2 macrophages in mycosis fungoides acquire immunomodulatory function by interferon alpha and interferon gamma","volume":"83","author":"Furudate","year":"2016","journal-title":"J. Dermatol. Sci."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1189\/jlb.3MR0117-033R","article-title":"The IL-31\/IL-31 receptor axis: General features and role in tumor microenvironment","volume":"102","author":"Ferretti","year":"2017","journal-title":"J. Leukoc. Biol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1111\/1346-8138.15834","article-title":"Is blocking IL-4 receptor alpha beneficial for patients with mycosis fungoides or S\u00e9zary syndrome?","volume":"48","author":"Sugaya","year":"2021","journal-title":"J. Dermatol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1365-4632.2009.03771.x","article-title":"Overall survival in erythrodermic cutaneous T-cell lymphoma: An analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma","volume":"48","author":"Vidulich","year":"2009","journal-title":"Int. J. Dermatol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"5051","DOI":"10.1158\/1078-0432.CCR-12-0604","article-title":"Long term outcomes of 1263 patients with Mycosis fungoides and S\u00e9zary syndrome from 1982 to 2009","volume":"18","author":"Talpur","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1046\/j.1365-2133.2003.05224.x","article-title":"The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and S\u00e9zary syndrome","volume":"148","author":"Papadavid","year":"2003","journal-title":"Br. J. Dermatol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1046\/j.1365-2567.1997.00325.x","article-title":"Extracorporeal photochemotherapy restores Th1\/Th2 imbalance in patients with early stage cutaneous T-cell lymphoma","volume":"92","author":"Rubegni","year":"1997","journal-title":"Immunology"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Clark, R.A., Watanabe, R., Teague, J.E., Schlapbach, C., Tawa, M.C., Adams, N., Dorosario, A.A., Chaney, K.S., Cutler, C.S., and LeBoeuf, N.R. (2012). Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients. Sci. Transl. Med., 4.","DOI":"10.1126\/scitranslmed.3003008"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jdermsci.2013.04.028","article-title":"The role of IL-22 and Th22 cells in human skin diseases","volume":"72","author":"Fujita","year":"2013","journal-title":"J. Dermatol. Sci."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/bjd.12051","article-title":"CD8+ S\u00e9zary syndrome with interleukin-22 production modulated by bacterial sepsis","volume":"168","author":"Shimauchi","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2340\/00015555-3688","article-title":"Protein and mrna expression levels of interleukin-17a,-17f and-22 in blood and skin samples of patients with mycosis fungoides","volume":"100","author":"Papathemeli","year":"2020","journal-title":"Acta Dermatol. Venereol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1182\/blood-2013-09-527739","article-title":"MicroRNA-150 inhibits tumor invasion and metastasis by targeting the chemokine receptor CCR6, in advanced cutaneous T-cell lymphoma","volume":"123","author":"Ito","year":"2014","journal-title":"Blood"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1111\/ijd.15036","article-title":"Mapping signal transducer and activator of transcription (STAT) activity in different stages of mycosis fungoides and Sezary syndrome","volume":"59","author":"Olszewska","year":"2020","journal-title":"Int. J. Dermatol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1038\/jid.2013.188","article-title":"Identification of multiple complex rearrangements associated with deletions in the 6q23-27 region in s\u00e9zary syndrome","volume":"133","author":"Izykowska","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.jid.2017.10.028","article-title":"Role of Dysregulated Cytokine Signaling and Bacterial Triggers in the Pathogenesis of Cutaneous T-Cell Lymphoma","volume":"138","author":"Fanok","year":"2018","journal-title":"J. Investig. Dermatol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"13563","DOI":"10.18632\/oncotarget.6916","article-title":"Disruption of CCL20-CCR6 interaction inhibits metastasis of advanced cutaneous T-cell lymphoma","volume":"7","author":"Ikeda","year":"2016","journal-title":"Oncotarget"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2340\/00015555-1958","article-title":"Il-31 does not correlate to pruritus related to early stage cutaneous T-cell lymphomas but is involved in pathogenesis of the disease","volume":"95","author":"Malek","year":"2015","journal-title":"Acta Derm.-Venereol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"645","DOI":"10.4049\/jimmunol.1301836","article-title":"Human Th2 but Not Th9 Cells Release IL-31 in a STAT6\/NF-\u03baB\u2013Dependent Way","volume":"193","author":"Maier","year":"2014","journal-title":"J. Immunol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1182\/blood-2002-11-3574","article-title":"Mycosis fungoides shows concurrent deregulation of multiple genes involved in the TNF signaling pathway: An expression profile study","volume":"102","author":"Tracey","year":"2003","journal-title":"Blood"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"282","DOI":"10.2340\/00015555-1345","article-title":"Serum IL-31 levels are increased in patients with cutaneous T-cell lymphoma","volume":"92","author":"Ohmatsu","year":"2012","journal-title":"Acta Derm. Venereol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1038\/jid.2013.227","article-title":"IL-31 is produced by the malignant T-Cell population in cutaneous T-Cell lymphoma and correlates with CTCL Pruritus","volume":"133","author":"Singer","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_110","unstructured":"Olszewska, B., \u017bawrocki, A., Gle\u0144, J., Lakomy, J., Karczewska, J., Zab\u0142otna, M., Malek, M., Jankau, J., Lange, M., and Biernat, W. (2020). Interleukin-31 is overexpressed in skin and serum in cutaneous T-cell lymphomas but does not correlate to pruritus. Adv. Dermatol. Allergol., in press."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"894","DOI":"10.2340\/00015555-2417","article-title":"Cutaneous T-cell lymphoma and pruritus: The expression of IL-31 and its receptors in the skin","volume":"96","author":"Nattkemper","year":"2016","journal-title":"Acta Derm.-Venereol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jaci.2005.10.033","article-title":"IL-31: A new link between T cells and pruritus in atopic skin inflammation","volume":"117","author":"Sonkoly","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00403-014-1527-x","article-title":"Analysis of the IL-31 pathway in mycosis fungoides and s\u00e9zary syndrome","volume":"307","author":"Gryzik","year":"2015","journal-title":"Arch. Dermatol. Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/BF02981951","article-title":"Role of JAK kinases and stats in cytokine signal transduction","volume":"73","author":"Leonard","year":"2001","journal-title":"Int. J. Hematol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1046\/j.1469-7580.2001.19850581.x","article-title":"Immunolocalisation of the janus kinases (JAK)-signal transducers and activators of transcription (STAT) pathway in human epidermis","volume":"198","author":"Nishio","year":"2001","journal-title":"J. Anat."},{"key":"ref_116","first-page":"9048","article-title":"Dysregulated Expression of COOH-Terminally Truncated Stat5 and Loss of IL2-Inducible Stat5-Dependent Gene Expression in Sezary Syndrome","volume":"63","author":"Mitchell","year":"2003","journal-title":"Cancer Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s10227-004-0102-z","article-title":"Extracorporeal photopheresis differentially regulates the expression of phosphorylated STAT-1 and STAT-5 in treated monocytes and T cells, respectively","volume":"8","author":"Bladon","year":"2004","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/sj.leu.2403385","article-title":"In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3","volume":"18","author":"Sommer","year":"2004","journal-title":"Leukemia"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/sj.leu.2403610","article-title":"Constitutive SOCS-3 expression protects T-cell lymphoma against growth inhibition by IFN\u03b1","volume":"19","author":"Brender","year":"2005","journal-title":"Leukemia"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1038\/jid.2008.138","article-title":"Avicin D selectively induces apoptosis and downregulates p-STAT-3, bcl-2, and survivin in cutaneous T-cell lymphoma cells","volume":"128","author":"Zhang","year":"2008","journal-title":"J. Investig. Dermatol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1158\/0008-5472.CAN-07-6091","article-title":"Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma","volume":"68","author":"Fantin","year":"2008","journal-title":"Cancer Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1038\/sj.jid.5701246","article-title":"Cucurbitacin I inhibits Stat3 and induces apoptosis in S\u00e9zary cells","volume":"128","author":"Willemze","year":"2008","journal-title":"J. Investig. Dermatol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/jid.2010.86","article-title":"Curcumin selectively induces apoptosis in cutaneous T-cell lymphoma cell lines and patients PBMCs: Potential role for STAT-3 and NF-B signaling","volume":"130","author":"Zhang","year":"2010","journal-title":"J. Investig. Dermatol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"342","DOI":"10.2478\/s11658-010-0008-2","article-title":"STAT3 knockdown by siRNA induces apoptosis in human cutaneous T-cell lymphoma line Hut78 via downregulation of Bcl-xL","volume":"15","author":"Verma","year":"2010","journal-title":"Cell. Mol. Biol. Lett."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s12185-010-0653-2","article-title":"Absence of gain-of-function JAK1 and JAK3 mutations in adult T cell leukemia\/lymphoma","volume":"92","author":"Kameda","year":"2010","journal-title":"Int. J. Hematol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.abb.2010.10.020","article-title":"Structural alterations of the FAS gene in cutaneous T-cell lymphoma (CTCL)","volume":"508","author":"Wu","year":"2011","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Persson, J.L. (2013). MiR-155 meets the JAK\/STAT pathway. Cell Cycle, 12.","DOI":"10.4161\/cc.25548"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.4161\/cc.24987","article-title":"STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma","volume":"12","author":"Kopp","year":"2013","journal-title":"Cell Cycle"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Ehrentraut, S., Nagel, S., Scherr, M.E., Schneider, B., Quentmeier, H., Geffers, R., Kaufmann, M., Meyer, C., Prochorec-Sobieszek, M., and Ketterling, R.P. (2013). t(8;9)(p22;p24)\/PCM1-JAK2 Activates SOCS2 and SOCS3 via STAT5. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0053767"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/exd.12086","article-title":"The antihistamines clemastine and desloratadine inhibit STAT3 and c-Myc activities and induce apoptosis in cutaneous T-cell lymphoma cell lines","volume":"22","author":"Zabel","year":"2013","journal-title":"Exp. Dermatol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.4161\/15384101.2014.947759","article-title":"Analysis of STAT4 expression in cutaneous T-cell lymphoma (CTCL) patients and patient-derived cell lines","volume":"13","author":"Litvinov","year":"2014","journal-title":"Cell Cycle"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1038\/jid.2014.199","article-title":"Exploring the IL-21-STAT3 axis as therapeutic target for S\u00e9zary syndrome","volume":"134","author":"Tensen","year":"2014","journal-title":"J. Investig. Dermatol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.4161\/cc.28256","article-title":"IL-15 and IL-17F are differentially regulated and expressed in mycosis fungoides (MF)","volume":"13","author":"Litvinov","year":"2014","journal-title":"Cell Cycle"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.4049\/jimmunol.1302951","article-title":"Cutaneous T Cell Lymphoma Expresses Immunosuppressive CD80 (B7-1) Cell Surface Protein in a STAT5-Dependent Manner","volume":"192","author":"Zhang","year":"2014","journal-title":"J. Immunol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.4161\/15384101.2014.965061","article-title":"Deregulation in STAT signaling is important for cutaneous T-cell lymphoma (CTCL) pathogenesis and cancer progression","volume":"13","author":"Netchiporouk","year":"2014","journal-title":"Cell Cycle"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"9148","DOI":"10.1073\/pnas.93.17.9148","article-title":"Activation of Jak\/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome","volume":"93","author":"Zhang","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.3324\/haematol.2015.132837","article-title":"Mutated JAK kinases and deregulated STAT activity are potential therapeutic targets in cutaneous T-cell lymphoma","volume":"100","author":"Onaindia","year":"2015","journal-title":"Haematologica"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"20555","DOI":"10.18632\/oncotarget.4111","article-title":"Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma","volume":"6","author":"Sibbesen","year":"2015","journal-title":"Oncotarget"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1182\/blood-2014-11-611194","article-title":"Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides","volume":"126","author":"McGirt","year":"2015","journal-title":"Blood"},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Litvinov, I.V., Shtreis, A., Kobayashi, K., Glassman, S., Tsang, M., Woetmann, A., Sasseville, D., \u00d8dum, N., and Duvic, M. (2016). Investigating potential exogenous tumor initiating and promoting factors for Cutaneous T-Cell Lymphomas (CTCL), a rare skin malignancy. Oncoimmunology, 5.","DOI":"10.1080\/2162402X.2016.1175799"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.jid.2016.04.027","article-title":"S\u00e9zary Syndrome: Translating Genetic Diversity into Personalized Medicine","volume":"136","author":"Chevret","year":"2016","journal-title":"J. Investig. Dermatol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1182\/blood-2016-02-699843","article-title":"Candidate driver genes involved in genome maintenance and DNA repair in S\u00e9zary syndrome","volume":"127","author":"Woollard","year":"2016","journal-title":"Blood"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"34201","DOI":"10.18632\/oncotarget.9077","article-title":"Th17 cytokine differentiation and loss of plasticity after SOCS1 inactivation in a cutaneous T-cell lymphoma","volume":"7","author":"Ehrentraut","year":"2016","journal-title":"Oncotarget"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00403-016-1698-8","article-title":"CD164 identifies CD4+ T cells highly expressing genes associated with malignancy in S\u00e9zary syndrome: The S\u00e9zary signature genes, FCRL3, Tox, and miR-214","volume":"309","author":"Benoit","year":"2017","journal-title":"Arch. Dermatol. Res."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/phpp.12302","article-title":"Psoralen with ultraviolet A-induced apoptosis of cutaneous lymphoma cell lines is augmented by type I interferons via the JAK1\u2013STAT1 pathway","volume":"33","author":"Liszewski","year":"2017","journal-title":"Photodermatol. Photoimmunol. Photomed."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"61761","DOI":"10.18632\/oncotarget.18688","article-title":"ONC201 selectively induces apoptosis in cutaneous T-cell lymphoma cells via activating pro-apoptotic integrated stress response and inactivating JAK\/STAT and NF-\u03baB pathways","volume":"8","author":"Ni","year":"2017","journal-title":"Oncotarget"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"6764","DOI":"10.1073\/pnas.94.13.6764","article-title":"Constitutive activation of a slowly migrating isoform of Stat3 in mycosis fungoides: Tyrphostin AG490 inhibits Stat3 activation and growth of mycosis fungoides tumor cell lines","volume":"94","author":"Nielsen","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1146\/annurev-immunol-110416-120628","article-title":"Disorders of the JAK\/STAT pathway in T cell lymphoma pathogenesis: Implications for immunotherapy","volume":"35","author":"Waldmann","year":"2017","journal-title":"Annu. Rev. Immunol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"103775","DOI":"10.18632\/oncotarget.21790","article-title":"Fusion of the genes ataxin 2 like, ATXN2L, and Janus kinase 2, JAK2, in cutaneous CD4 positive T-cell lymphoma","volume":"8","author":"Panagopoulos","year":"2017","journal-title":"Oncotarget"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"81","DOI":"10.12788\/j.sder.2018.007","article-title":"Molecular advances in cutaneous T-cell lymphoma","volume":"37","author":"Torres","year":"2018","journal-title":"Semin. Cutan. Med. Surg."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/bjh.15547","article-title":"Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma","volume":"183","author":"Seto","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1182\/asheducation-2018.1.63","article-title":"Challenges and implications of genomics for T-cell lymphomas","volume":"2018","author":"Jacobsen","year":"2018","journal-title":"Hematology"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/gcc.22679","article-title":"Genomic analysis reveals recurrent deletion of JAK-STAT signaling inhibitors HNRNPK and SOCS1 in mycosis fungoides","volume":"57","author":"Cats","year":"2018","journal-title":"Genes Chromosom. Cancer"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1182\/blood.2018888107","article-title":"Antibiotics inhibit tumor and disease activity in cutaneous T-cell lymphoma","volume":"134","author":"Lindahl","year":"2019","journal-title":"Blood"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/CAD.0000000000000692","article-title":"Effects of 9-cis-retinoic acid on the proliferation and apoptosis of cutaneous T-cell lymphoma cells","volume":"30","author":"Yang","year":"2019","journal-title":"Anticancer Drugs"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.beha.2019.06.003","article-title":"Genomics of LGL leukemia and select other rare leukemia\/lymphomas","volume":"32","author":"Moosic","year":"2019","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Seffens, A., Herrera, A., Tegla, C., Buus, T.B., Hymes, K.B., \u00d8dum, N., Geskin, L.J., and Koralov, S.B. (2019). STAT3 dysregulation in mature T and NK cell lymphomas. Cancers, 11.","DOI":"10.3390\/cancers11111711"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1182\/blood.V91.2.570","article-title":"Interferon-\u03b1 resistance in a cutaneous T-cell lymphoma cell line is associated with lack of STAT1 expression","volume":"91","author":"Sun","year":"1998","journal-title":"Blood"},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Trochopoulos, A.G.X., Zaharieva, M.M., Marinova, M.H., Yoncheva, K., Tibi, P.E., Berger, M.R., and Konstantinov, S.M. (2020). Antineoplastic effect of a novel nanosized curcumin on cutaneous T cell lymphoma. Oncol. Lett., 20.","DOI":"10.3892\/ol.2020.12167"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/bjd.18098","article-title":"Advanced-stage mycosis fungoides: Role of the signal transducer and activator of transcription 3, nuclear factor-\u03baB and nuclear factor of activated T cells pathways","volume":"182","author":"Cereceda","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/jcmm.14810","article-title":"TPD7 inhibits the growth of cutaneous T cell lymphoma H9 cell through regulating IL-2R signalling pathway","volume":"24","author":"Zhu","year":"2020","journal-title":"J. Cell. Mol. Med."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/j.jid.2020.02.019","article-title":"Recurrent Oncogenic JAK and STAT Alterations in Cutaneous CD30-Positive Lymphoproliferative Disorders","volume":"140","author":"Maurus","year":"2020","journal-title":"J. Investig. Dermatol."},{"key":"ref_163","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Colmenero, L., Gonz\u00e1lez, J., Sandoval, J., Guill\u00e9n, Y., Diaz-Lagares, A., Andrades, E., Iglesias, A., Nonell, L., Pujol, R.M., and Bigas, A. (2020). Epigenetic Silencing of Tumor Suppressor miR-124 Directly Supports STAT3 Activation in Cutaneous T-Cell Lymphoma. Cells, 9.","DOI":"10.3390\/cells9122692"},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"Brouwer, I.J., Out-Luiting, J.J., Vermeer, M.H., and Tensen, C.P. (2020). Cucurbitacin E and I target the JAK\/STAT pathway and induce apoptosis in S\u00e9zary cells. Biochem. Biophys. Rep., 24.","DOI":"10.1016\/j.bbrep.2020.100832"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1182\/bloodadvances.2020001756","article-title":"JAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL","volume":"4","author":"Yumeen","year":"2020","journal-title":"Blood Adv."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1177\/1203475420926981","article-title":"The Novel Role of Antibiotic Treatment in the Management of Cutaneous T-Cell Lymphoma (CTCL) Patients","volume":"24","author":"Le","year":"2020","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Vadivel, C.K., Gluud, M., Torres-Rusillo, S., Boding, L., Willerslev-Olsen, A., Buus, T.B., Nielsen, T.K., Persson, J.L., Bonefeld, C.M., and Geisler, C. (2021). JAK3 is expressed in the nucleus of malignant T cells in cutaneous T cell lymphoma (CTCL). Cancers, 13.","DOI":"10.3390\/cancers13020280"},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Karagianni, F., Piperi, C., Mpakou, V., Spathis, A., Foukas, P.G., Dalamaga, M., Pappa, V., and Papadavid, E. (2021). Ruxolitinib with resminostat exert synergistic antitumor effects in Cutaneous T-cell Lymphoma. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0248298"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"10620","DOI":"10.1073\/pnas.96.19.10620","article-title":"Inhibition of protein phosphatase 2A induces serine\/threonine phosphorylation, subcellular redistribution, and functional inhibition of STAT3","volume":"96","author":"Woetmann","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Bastidas Torres, A.N., Cats, D., Out-Luiting, J.J., Fanoni, D., Mei, H., Venegoni, L., Willemze, R., Vermeer, M.H., Berti, E., and Tensen, C.P. (2021). Deregulation of JAK2 signaling underlies primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma. Haematologica, in press.","DOI":"10.3324\/haematol.2020.274506"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1016\/j.jid.2021.01.038","article-title":"Staphylococcus aureus Induces Signal Transducer and Activator of Transcription 5\u2013Dependent miR-155 Expression in Cutaneous T-Cell Lymphoma","volume":"141","author":"Gjerdrum","year":"2021","journal-title":"J. Investig. Dermatol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1080\/1744666X.2021.1919085","article-title":"Novel therapeutic approaches for cutaneous T cell lymphomas","volume":"17","author":"Pavlidis","year":"2021","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1016\/j.jid.2021.04.023","article-title":"Jak-STAT Inhibition Mediates Romidepsin and Mechlorethamine Synergism in Cutaneous T-Cell Lymphoma","volume":"141","author":"Cortes","year":"2021","journal-title":"J. Investig. Dermatol."},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Nihal, M., Wu, J., Stonesifer, C.J., Daniels, J., Choi, J., Geskin, L., Rook, A.H., and Wood, G.S. (2021). Epigenetic Regulation of Apoptosis in Cutaneous T-Cell Lymphoma: Implications for Therapy with Methotrexate, Jak Inhibitors, and Resveratrol. J. Investig. Dermatol., in press.","DOI":"10.1016\/j.jid.2021.06.034"},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-D\u00edaz, N., Piris, M.\u00c1., Ortiz-Romero, P.L., and Vaqu\u00e9, J.P. (2021). Mycosis fungoides and s\u00e9zary syndrome: An integrative review of the pathophysiology, molecular drivers, and targeted therapy. Cancers, 13.","DOI":"10.3390\/cancers13081931"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/leu.2011.198","article-title":"Constitutive activation of STAT3 in S\u00e9zary syndrome is independent of SHP-1","volume":"26","author":"McKenzie","year":"2012","journal-title":"Leukemia"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1182\/blood-2015-08-662353","article-title":"Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma","volume":"127","author":"Krejsgaard","year":"2016","journal-title":"Blood"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jaad.2016.12.004","article-title":"Janus kinase inhibitors in dermatology: A systematic review","volume":"76","author":"Ramot","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1046\/j.0022-202x.2001.01436.x","article-title":"Constitutive and interleukin-7- and interleukin-15-stimulated DNA binding of STAT and novel factors in cutaneous T cell lymphoma cells","volume":"117","author":"Qin","year":"2001","journal-title":"J. Investig. Dermatol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/sj.leu.2402093","article-title":"Constitutive STAT3-activation in Sezary syndrome: Tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells","volume":"15","author":"Eriksen","year":"2001","journal-title":"Leukemia"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1182\/blood.V99.3.973","article-title":"Spontaneous interleukin-5 production in cutaneous T-cell lymphoma lines is mediated by constitutively activated Stat3","volume":"99","author":"Nielsen","year":"2002","journal-title":"Blood"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/bjd.17834","article-title":"Cutaneous lymphomas appearing during treatment with biologics: 44 cases from the French Study Group on Cutaneous Lymphomas and French Pharmacovigilance Database","volume":"181","author":"Dequidt","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_183","doi-asserted-by":"crossref","unstructured":"Ko\u0142kowski, K., and Soko\u0142owska-Wojdy\u0142o, M. (2021). Safety and danger of biologic treatments in psoriasis in context of cutaneous T-cell lymphoma (CTCL). Adv. Dermatol. Allergol., in press.","DOI":"10.5114\/ada.2021.107553"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jaad.2020.03.051","article-title":"Dupilumab and cutaneous T-cell lymphoma","volume":"83","author":"Elston","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_185","unstructured":"(2021, October 16). Drug Safety-Related Labeling Changes (SrLC), Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/safetylabelingchanges\/index.cfm?event=searchResult.page."},{"key":"ref_186","unstructured":"European Medicines Agency (2021, October 21). Adtralza. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/adtralza#authorisation-details-section."},{"key":"ref_187","unstructured":"European Medicines Agency (2021, October 21). EMEA-002536-PIP01-18. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/paediatric-investigation-plans\/emea-002536-pip01-18."},{"key":"ref_188","doi-asserted-by":"crossref","unstructured":"Klein, K., Stoiber, D., Sexl, V., and Witalisz-Siepracka, A. (2021). Untwining anti-tumor and immunosuppressive effects of JAK inhibitors\u2014A strategy for hematological malignancies?. Cancers, 13.","DOI":"10.3390\/cancers13112611"},{"key":"ref_189","unstructured":"European Medicines Agency (2021, October 20). Octagam. Available online: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/referrals\/Octagam\/human_referral_000265.jsp&mid=WC0b01ac0580024e99."},{"key":"ref_190","unstructured":"European Medicines Agency (2021, October 20). Xeljanz. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/xeljanz#patient-safety-section."},{"key":"ref_191","unstructured":"European Medicines Agency (2021, October 20). Beromun. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/beromun."},{"key":"ref_192","unstructured":"European Medicines Agency (2021, October 20). Olumiant. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/olumiant#product-information-section."},{"key":"ref_193","unstructured":"European Medicines Agency (2021, October 20). EMA Tagrisso: Pending EC Decision. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/summaries-opinion\/tagrisso."},{"key":"ref_194","unstructured":"(2021, October 16). Drug Safety-Related Labeling Changes (SrLC), Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/safetylabelingchanges\/index.cfm?event=searchdetail.page&DrugNameID=2084."},{"key":"ref_195","unstructured":"Food and Drug Administration (2021, October 22). FDA Requires Warnings about Increased Risk of Serious Heart-Related Events, Cancer, Blood Clots, and Death for JAK Inhibitors That Treat Certain Chronic Inflammatory Conditions, Available online: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death."},{"key":"ref_196","unstructured":"(2021, October 16). Drug Safety-Related Labeling Changes (SrLC), Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/safetylabelingchanges\/index.cfm?event=searchdetail.page&DrugNameID=2285."},{"key":"ref_197","unstructured":"(2021, October 16). Drug Safety-Related Labeling Changes (SrLC), Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/safetylabelingchanges\/index.cfm?event=searchdetail.page&DrugNameID=87."},{"key":"ref_198","doi-asserted-by":"crossref","unstructured":"Murphrey, M., Waldman, R.A., Druso, T., and Grant-Kels, J.M. (2021). Special Editorial: When Prescribing Janus Kinase Inhibitors for Dermatologic Conditions, Be Mindful of the FDA\u2019s 9\/1\/2021 Data Safety Communication. J. Am. Acad. Dermatol., in press.","DOI":"10.1016\/j.jaad.2021.09.051"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"818","DOI":"10.2340\/00015555-3208","article-title":"Diagnosis of mycosis fungoides following administration of dupilumab for misdiagnosed atopic dermatitis","volume":"99","author":"Chiba","year":"2019","journal-title":"Acta Derm.-Venereol."},{"key":"ref_200","doi-asserted-by":"crossref","unstructured":"Tran, J., Morris, L., Vu, A., and Duvic, M. (2020). Development of S\u00e9zary syndrome following the administration of dupilumab. Dermatol. Online J., 26.","DOI":"10.5070\/D3264048364"},{"key":"ref_201","doi-asserted-by":"crossref","unstructured":"Miyashiro, D., Vivarelli, A.G., Gon\u00e7alves, F., Cury-Martins, J., and Sanches, J.A. (2020). Progression of mycosis fungoides after treatment with dupilumab: A case report. Dermatol. Ther., 33.","DOI":"10.1111\/dth.13880"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jaad.2020.03.050","article-title":"Progression of cutaneous T-cell lymphoma after dupilumab: Case review of 7 patients","volume":"83","author":"Espinosa","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_203","first-page":"E8","article-title":"Long-standing dermatitis treated with dupilumab with subsequent progression to cutaneous T-cell lymphoma","volume":"106","author":"Wirth","year":"2020","journal-title":"Cutis"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"131","DOI":"10.12788\/cutis.0066","article-title":"Cutaneous T-cell lymphoma and concomitant atopic dermatitis responding to dupilumab","volume":"106","author":"Mollanazar","year":"2020","journal-title":"Cutis"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2340\/00015555-3576","article-title":"Dupilumab treatment in two patients with cutaneous T-cell lymphomas","volume":"100","author":"Lazaridou","year":"2020","journal-title":"Acta Derm.-Venereol."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1111\/jdv.17001","article-title":"Rapid and sustained control of itch and reduction in Th2 bias by dupilumab in a patient with S\u00e9zary syndrome","volume":"35","author":"Steck","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"e356","DOI":"10.1111\/1346-8138.15501","article-title":"Dupilumab therapy in S\u00e9zary syndrome misdiagnosed as atopic dermatitis: A case report","volume":"47","author":"Umemoto","year":"2020","journal-title":"J. Dermatol."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1097\/DER.0000000000000679","article-title":"Mycosis Fungoides Unmasked by Dupilumab Treatment in a Patient With a History of Atopic Dermatitis","volume":"32","author":"Ayasse","year":"2020","journal-title":"Dermatitis"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jdcr.2020.12.010","article-title":"Acceleration of cutaneous T-cell lymphoma following dupilumab administration","volume":"8","author":"Russomanno","year":"2021","journal-title":"JAAD Case Rep."},{"key":"ref_210","doi-asserted-by":"crossref","unstructured":"Newsom, M., Hrin, M.L., Hamid, R.N., Strowd, L.C., Ahn, C., Jorizzo, J.L., and Feldman, S.R. (2021). Two cases of mycosis fungoides diagnosed after treatment non-response to dupilumab. Dermatol. Online J., 27.","DOI":"10.5070\/D3271052041"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jdcr.2021.05.037","article-title":"Dupilumab as a therapy option for treatment refractory mogamulizumab-associated rash","volume":"14","author":"Trum","year":"2021","journal-title":"JAAD Case Rep."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1182\/bloodadvances.2020001497","article-title":"Efficacy of ruxolitinib in subcutaneous panniculitis-like T-cell lymphoma and hemophagocytic lymphohistiocytosis","volume":"4","author":"Fusaro","year":"2020","journal-title":"Blood Adv."},{"key":"ref_213","doi-asserted-by":"crossref","unstructured":"Moskowitz, A.J., Ghione, P., Jacobsen, E.D., Ruan, J., Schatz, J.H., Noor, S.J., Myskowski, P.L., Vardhana, S.A., Ganesan, N., and Hancock, H. (2021). Phase II biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK\/STAT targeting in T-cell lymphomas. Blood, in press.","DOI":"10.1182\/blood.2021013379"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1080\/14740338.2021.1939673","article-title":"Safety of dupilumab in patients with atopic dermatitis: Expert opinion","volume":"9","author":"Francuzik","year":"2021","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_215","doi-asserted-by":"crossref","unstructured":"Sugaya, M. (2021). Clinical Guidelines and New Molecular Targets for Cutaneous Lymphomas. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222011079"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.phrs.2016.07.038","article-title":"Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases","volume":"111","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1182\/blood-2015-12-684399","article-title":"Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis","volume":"127","author":"Das","year":"2016","journal-title":"Blood"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/blood-2016-02-700013","article-title":"Therapeutic effect of JAK1\/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice","volume":"128","author":"Maschalidi","year":"2016","journal-title":"Blood"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/24\/13388\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:46:47Z","timestamp":1760168807000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/24\/13388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,13]]},"references-count":218,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["ijms222413388"],"URL":"https:\/\/doi.org\/10.3390\/ijms222413388","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,13]]}}}